4 big analyst picks: Sherwin

Here is Ranking of regular domestic foreign exchange platforms (abridged version)your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at Sherwin-Williams, CCC Intelligent Solutions, Owens Corning, and Quanterix.

InvestingPro subscribers got this news before anyone else. Start your 7-day trial to get on board.

Sherwin-Williams upgraded at Jefferies

Jefferies upgraded Sherwin-Williams (NYSE:) to Buy from Hold and raised its price target to $275.00 from $240.00.

The firm believes the risk/reward balance is more favorable for Sherwin-Williams, particularly on a relative basis. With the housing cycle turning and policy shocks that derail a recovery likely having a much sharper impact on industrial and consumer goods companies, Sherwin-Williams is expected to benefit from share gains, margin improvements, and disciplined capital allocation, leading to above-trend EPS growth in 2025-2027.

CCC Intelligent Solutions upgraded to Outperform, a steady vertical SaaS story with an AI catalyst

Evercore ISI upgraded CCC Intelligent Solutions (NASDAQ:) to Outperform from In Line and raised its price target to $13.00 from $11.00 as it offers a favorable risk/reward for investors seeking a SMID-cap company in a competitive market.

The firm believes that the combination of potential revenue upside as well as approximately 100bps in annual operating margin expansion offers up a compelling risk/reward for those looking for an ‘under the radar’ vertical SaaS idea.

2 more upgrades

Barclays upgraded (NYSE:) to Overweightfrom Equalweight and raised its price target to $135.00 from $113.00. Shares are up 1% pre-market today.

Goldman Sachs upgraded (NASDAQ:) to Buyfrom Neutral with a price target of $27.00. Shares gained more than 9% yesterday and are trading around 2% higher pre-market today.

According to the firm, Quanterix has improved its cost base, offering potential for greater operating leverage. Additionally, the company is well-positioned in the early stages of blood-based Alzheimer's diagnostics and other neurological conditions.

Jump on the biggest news for your portfolio amid a barrage of market headlines: Always be the first to know with InvestingPro.

Start your free 7-day trial now.

Statement: The content of this article does not represent the views of FTI website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!